StockNews.AI
BCAB
StockNews.AI
153 days

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

1. BCAB will host a Q4 and full-year 2024 earnings call on March 27. 2. The company develops CAB therapeutics for solid tumors with lower toxicity. 3. BCAB holds over 780 global patents, enhancing market positioning. 4. Two CAB programs are in Phase 2 testing, indicating strong pipeline potential. 5. The proprietary technology aims for more selective and cost-effective treatments.

5m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings call could reveal positive financial results and business insights, potentially elevating investor confidence. Historically, biotech earnings calls can lead to price increases if positive news is disclosed, as seen with companies like Moderna during their expansive product pipeline announcements.

How important is it?

The earnings call can significantly impact Base's stock price through potential favorable financial updates and insights into product pipelines and patent coverage. Strong fundamentals and developments in trial phases suggest a heightened chance for positive market reception.

Why Short Term?

The earnings call on March 27 could lead to immediate market reactions. Similar patterns occurred with other biotech stocks where investor responses to quarterly results impacted stock prices significantly within days.

Related Companies

MRNACRISNVAXREGN
March 19, 2025 08:00 ET  | Source: BioAtla, Inc. SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights. Conference Call and Webcast Information        Date: Thursday, March 27, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Fourth Quarter and Full-Year 2024 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Conference ID: BIOATLA The press release with the financial results will be accessible prior to the conference call through “News Releases” in the News & Events section of the company’s website. A replay of the call will also be available through “Events & Presentations” in the Investors section of the company’s website. About BioAtla®, Inc. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The Company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.  Internal Contact:Richard WaldronChief Financial OfficerBioAtla, Inc.rwaldron@bioatla.com 858.356.8945 External Contact:Bruce MackleLifeSci Advisors, LLCbmackle@lifesciadvisors.com

Related News